Thanks to visit codestin.com
Credit goes to link.springer.com

Skip to main content
Log in

MAPK signaling pathway-targeted marine compounds in cancer therapy

  • Review – Cancer Research
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

This paper reviews marine compounds that target the mitogen-activated protein kinase (MAPK) signaling pathway and their main sources, chemical structures, major targeted cancers and possible mechanisms to provide comprehensive and basic information for the development of marine compound-based antitumor drugs in clinical cancer therapy research.

Methods

This paper searched the PubMed database using the keywords “cancer”, “marine*” and “MAPK signaling pathway”; this search was supplemented by the literature-tracing method. The marine compounds screened for review in this paper are pure compounds with a chemical structure and have antitumor effects on more than one tumor cell line by targeting the MAPK signaling pathway. The PubChem database was used to search for the PubMed CID and draw the chemical structures of the marine compounds.

Results

A total of 128 studies were searched, and 32 marine compounds with unique structures from extensive sources were collected for this review. These compounds are cytotoxic to cancer cell lines, although their targets are still unclear. This paper describes their anticancer effect mechanisms and the protein expression changes in the MAPK pathway induced by these marine compound treatments. This review is the first to highlight MAPK signaling pathway-targeted marine compounds and their use in cancer therapy.

Conclusion

The MAPK signaling pathway is a promising potential target for cancer therapy. Searching for marine compounds that exert anticancer effects by targeting the MAPK signaling pathway and developing them into new marine anticancer drugs will be beneficial for cancer treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+
from £29.99 /Month
  • Starting from 10 chapters or articles per month
  • Access and download chapters and articles from more than 300k books and 2,500 journals
  • Cancel anytime
View plans

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

AKT:

Protein kinase B

CDC:

Cell division cycle

Csps:

Colonospheres

Cyt C:

Cytochrome C

DR5:

Death receptor 5

EGFR:

Epidermal growth factor receptor

EMA:

European Medicines Agency

EMT:

Epithelial–mesenchymal transition

ERK:

Extracellular signal-regulated kinase

FADD:

Fas-associating protein with a novel death domain

GRB2:

Growth factor receptor-bound protein 2

HCC:

Hepatocellular carcinoma

HIF-1α:

Hypoxia inducible factor-1α

IGF:

Insulin-like growth factor

JNK:

C-Jun N-terminal kinase

MAPK:

Mitogen-activated protein kinase

MEK:

Mitogen-activated protein kinase kinase

MEKK4:

Mitogen-activated protein kinase kinase kinase 4

MKK3:

Mitogen-activated protein kinase kinase 3

MMP:

Mitochondrial membrane potential

MMP-2/-9:

Matrix metalloproteinase 2/9

mTOR:

Mammalian target of rapamycin

NF-κB:

Nuclear factor kappa-B

NSCLC:

Nonsmall cell lung cancer

PARP:

Polymerase (ADP-ribose) polymerase

PI3K:

Phosphatidylinositol 3 kinase

PIM2:

Recombinant Pim-2 Oncogene

PKC:

Protein kinase C

ROS:

Reactive oxygen species

SAPK:

Stress-activated protein kinase

TNBC:

Triple-negative breast cancer

TRAIL:

Tumor necrosis factor-related apoptosis-inducing ligand

uPA:

Urokinase-type plasminogen activator

FxOH:

Fucoxanthinol

Lam:

Laminarin

SA:

Salternamide A

Mer:

Mertensene

SE11:

1′-Deoxyrhodoptilometrin

SE16:

(S)-(−)-Rhodoptilometrin

SB:

Siphonodictyal B

(19Z)-HCA:

(19Z)-Halichondramide

Apl:

Aplysin

Asp A:

Asperolide A

DA:

Dihydroaustrasulfone alcohol

C800:

Crambescidin 800

C828:

Aurantoside C

Lep A:

Leptaochotensosides A

FC:

Fumigaclavine C

Pli:

Plitidepsin

MA:

Mycalamide A

Pt-A:

Ptilomycalin A

Pch-A:

Pulchranin A

12-dea-12-ES:

12-Deacetyl-12-epi-scalaradial

Fuc:

Fucoidan

Momc:

Monanchoxymycalin c

FX:

Fucoxanthin

STD:

Stichoposide D

11-epi-SA:

11-Epi-sinulariolide acetate

WB:

Wentilactone B

EPA:

Eupalmerin acetate

BBA:

Bisebromoamide

GA:

Gentisyl alcohol

References

Download references

Acknowledgements

We thank American Journal Experts for their help in revising the English grammar.

Funding

This work was supported by the National Natural Science Foundation of China (31770774), the Provincial Major Project of Basic or Applied Research in Natural Science, Guangdong Provincial Education Department (2016KZDXM038) and the Higher Education Reform Project of Guangdong Province (2019268).

Author information

Authors and Affiliations

Authors

Contributions

ZH and JW contributed to the design and conception of the study; RL and XH performed the information retrieval and analysis; JW, RL, XH, TL and ZZ wrote the manuscript; TL and ZZ created the table and figures; and ZH guided the manuscript writing and provided financial support. Additionally, all the authors read and approved the final manuscript.

Corresponding author

Correspondence to Zunnan Huang.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Figure S.

Flow diagram of the process to select eligible studies; “n” represents the number of studies retrieved (TIF 8267 KB)

Supplementary file2 (DOCX 16 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wei, J., Liu, R., Hu, X. et al. MAPK signaling pathway-targeted marine compounds in cancer therapy. J Cancer Res Clin Oncol 147, 3–22 (2021). https://doi.org/10.1007/s00432-020-03460-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1007/s00432-020-03460-y

Keywords